WallStSmart

Akso Health Group ADR (AHG)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 481172% more annual revenue ($66.57B vs $13.83M). MRK leads profitability with a 4.8% profit margin vs -135.0%. MRK earns a higher WallStSmart Score of 36/100 (F).

AHG

Avoid

15

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 5.3Quality: 9.0
Piotroski: 5/9Altman Z: 12.00

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHGUndervalued (+10.2%)

Margin of Safety

+10.2%

Fair Value

$1.57

Current Price

$0.84

$0.73 discount

UndervaluedFair: $1.57Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHG2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
12.0010/10

Safe zone — low bankruptcy risk

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

AHG4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$625.57M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-89.4%2/10

ROE of -89.4% — below average capital efficiency

Revenue GrowthGrowth
-12.9%2/10

Revenue declined 12.9%

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : AHG

The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : AHG

The primary concerns for AHG are EPS Growth, Market Cap, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

AHG profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

MRK carries more volatility with a beta of 0.23 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 15/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akso Health Group ADR

HEALTHCARE · MEDICAL DISTRIBUTION · China

Akso Health Group ADR is a leading entity in the healthcare sector, dedicated to providing innovative medical solutions and comprehensive patient care services. With a strong emphasis on advanced health technologies, the company is strategically positioned in the telehealth and personalized medicine markets, supported by a robust research and development framework. As it navigates the rapidly evolving healthcare landscape, Akso Health Group presents an attractive investment opportunity for institutional investors seeking to capitalize on transformative trends within the industry.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?